Pipeline Database
UB498
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB498
IndicationsMalignant neoplasm; Infection
ClinicalCN - Preclinical
TherapeuticsMedical Devices & Diagnostics
ModalitiesCGT
Exclusive Summary
- A CRISPR/Cas gene editing technology platform with completely independent intellectual property rights, ensuring Freedom to Operate by bypassing complex global patent barriers.
- Offers dual potential in diagnostics and prevention: applicable for early cancer screening (detecting circulating DNA/RNA) and the control of infectious diseases.
- Currently in the preclinical research stage, presenting a prime opportunity for global partners seeking early-stage technology licensing or co-development of next-gen diagnostic tools.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →